Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Mennecier

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Cancers|April 12, 2022
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 StudyRenaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, et al.
ERJ Open Research|February 17, 2018
Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i><sup>+</sup> advanced non-small cell lung cancer patientsJacques Cadranel, Alexis B Cortot, Hervé Lena, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2018
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective CohortClaire Merveilleux du Vignaux, Eric Dansin, Laurent Mhanna, et al.
Clinical Lung Cancer|October 26, 2019
Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE TrialJaafar Bennouna, Nicolas Girard, Clarisse Audigier-Valette, et al.
Cancer Medicine|May 31, 2018
SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patientsCamille Emprou, Pauline Le Van Quyen, Jérémie Jégu, et al.
Oncotarget|April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyMichaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.
The European Respiratory Journal|October 12, 2013
Second-line therapy in elderly patients with advanced nonsmall cell lung cancerElisabeth Quoix, Virginie Westeel, Lionel Moreau, et al.
European Journal of Cancer (Oxford, England : 1990)|December 29, 2021
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC networkArthur Petat, Eric Dansin, Fabien Calcagno, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid CarcinomaCharlotte Domblides, Karen Leroy, Isabelle Monnet, et al.
Lung Cancer (Amsterdam, Netherlands)|September 20, 2024
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutationDavid M Waterhouse, Sacha Rothschild, Christophe Dooms, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Cancers|April 12, 2022
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 StudyRenaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, et al.
ERJ Open Research|February 17, 2018
Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i><sup>+</sup> advanced non-small cell lung cancer patientsJacques Cadranel, Alexis B Cortot, Hervé Lena, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2018
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective CohortClaire Merveilleux du Vignaux, Eric Dansin, Laurent Mhanna, et al.
Clinical Lung Cancer|October 26, 2019
Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE TrialJaafar Bennouna, Nicolas Girard, Clarisse Audigier-Valette, et al.
Cancer Medicine|May 31, 2018
SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patientsCamille Emprou, Pauline Le Van Quyen, Jérémie Jégu, et al.
Oncotarget|April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyMichaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.
The European Respiratory Journal|October 12, 2013
Second-line therapy in elderly patients with advanced nonsmall cell lung cancerElisabeth Quoix, Virginie Westeel, Lionel Moreau, et al.
European Journal of Cancer (Oxford, England : 1990)|December 29, 2021
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC networkArthur Petat, Eric Dansin, Fabien Calcagno, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid CarcinomaCharlotte Domblides, Karen Leroy, Isabelle Monnet, et al.
Lung Cancer (Amsterdam, Netherlands)|September 20, 2024
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutationDavid M Waterhouse, Sacha Rothschild, Christophe Dooms, et al.
Pageof 5